ArticleCureus2026
When the Cure Turns Into a Culprit: Mesalamine and the Eosinophilic Lung.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a 74-year-old man with a one-year history of ulcerative colitis in remission who developed low-grade fever, dry cough, progressive dyspnea, loss of appetite, and an eight-kg weight loss over 12 weeks. Oral mesalamine (2.4 g/day) had been initiated 12 weeks before presentation, with respiratory symptoms developing approximately three weeks after initiation. Despite initial antibiotic therapy, his symptoms progressively worsened, and he developed hypoxemia requiring hospitalization. Investigations revealed leukocytosis with marked peripheral eosinophilia, elevated C-reactive protein (CRP) levels, and bilateral upper lobe- and peripheral-predominant pulmonary consolidations and ground-glass opacities. Infectious, parasitic, autoimmune, and malignant causes were investigated, and no alternative cause was identified. Transbronchial lung biopsy demonstrated eosinophil-rich subacute to chronic inflammation with organizing pneumonia-like changes, supporting eosinophilic pneumonia in the appropriate clinical context. The temporal relationship between mesalamine exposure and symptom onset, peripheral eosinophilia, compatible radiological and histopathological findings, and exclusion of alternative causes supported a diagnosis of mesalamine-associated eosinophilic pneumonia. Mesalamine was discontinued, and systemic corticosteroids were initiated concurrently, followed by rapid clinical improvement and subsequent complete radiological resolution. As both interventions were instituted simultaneously, the response could not be attributed independently to mesalamine withdrawal or corticosteroid therapy. This case highlights the importance of considering mesalamine-associated eosinophilic pneumonia in patients who develop respiratory symptoms and peripheral eosinophilia after mesalamine initiation. We also present a review of previously reported cases of 5-aminosalicylic acid (5-ASA)-associated eosinophilic respiratory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.